Malignant Intestinal Neoplasm

Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.

PMID 19001320 · Di Nicolantonio et al., 2008 · Open in CIViC

In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy o… (full text at CIViC)

PMID 29431699 · Corcoran et al., 2018 · Open in CIViC

In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and… (full text at CIViC)

PMID 26460303 · Kopetz et al., 2015 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 2 pati… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

In a clinical study of 122 cancer patients, including 37 previously treated colorectal cancer patients harboring BRAF V600 (V600E=32; V600 unknown=5) mutations, stable disease and progressive disease … (full text at CIViC)

PMID 26287849 · Hyman et al., 2015 · Open in CIViC

Five colorectal cancer (CRC) cell lines (VACO432, HT29, SNU-C5, KM20, WiDr) with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell li… (full text at CIViC)

PMID 22281684 · Prahallad et al., 2012 · Open in CIViC

This preclinical study examined vemurafenib efficacy on various colorectal cancer cell lines and in mouse xenograft experiments. Of the cell lines tested, six harbored BRAF V600E (and WT KRAS) and thr… (full text at CIViC)

PMID 22180495 · Yang et al., 2012 · Open in CIViC

In an in vitro study, WiDr, HT-29, LS411N, and SW1417 cell lines expressing BRAF V600E and treated with vemurafenib and erlotinib, or vemurafenib and gefitinib were associated with a reduction in cell… (full text at CIViC)

PMID 22448344 · Corcoran et al., 2012 · Open in CIViC

Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 with appendiceal cancer). Six of 17 evaluable patients achieved an objective response, 15 patients tota… (full text at CIViC)

PMID 27729313 · Hong et al., 2016 · Open in CIViC

Thirty-two patients with BRAF V600E positive metastatic colorectal cancer (mCRC) and 7 patients with other cancers were treated with a combination of BRAF-inhibitor vemurafenib (960 mg twice daily) an… (full text at CIViC)

PMID 36638198 · Tan et al., 2023 · Open in CIViC

This in vivo study examined the efficacy of various treatments on athymic nude mice xenografted with colorectal cancer HT29 cells, which harbor BRAF V600E. The authors sought to understand whether the… (full text at CIViC)

PMID 22180495 · Yang et al., 2012 · Open in CIViC

Five colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGF… (full text at CIViC)

PMID 22281684 · Prahallad et al., 2012 · Open in CIViC

5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified E… (full text at CIViC)

PMID 22281684 · Prahallad et al., 2012 · Open in CIViC

Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy. Two patien… (full text at CIViC)

PMID 25589621 · Yaeger et al., 2015 · Open in CIViC

Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subse… (full text at CIViC)

PMID 27325282 · Pietrantonio et al., 2016 · Open in CIViC

Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient h… (full text at CIViC)

PMID 27729313 · Hong et al., 2016 · Open in CIViC

COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF … (full text at CIViC)

PMID 21098728 · Corcoran et al., 2010 · Open in CIViC

Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient a… (full text at CIViC)

PMID 27729313 · Hong et al., 2016 · Open in CIViC

Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. Three patient… (full text at CIViC)

PMID 27729313 · Hong et al., 2016 · Open in CIViC

Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. Three patient… (full text at CIViC)

PMID 27729313 · Hong et al., 2016 · Open in CIViC

In a study of 468 colorectal adenocarcinoma 61 patients had micro-satellite instability (MSI) and there was a marginally statistically significantly better prognosis for BRAF WT (n=26) patients relati… (full text at CIViC)

PMID 27302369 · Schell et al., 2016 · Open in CIViC

5577 colon carcinoma tumors were evaluated for BRAF, KRAS, and mismatch repair status. From those successfully evaluated, 201 had microsatellite instability (MSI or MSI-H) and BRAF V600E, 72 had MSI a… (full text at CIViC)

PMID 28040692 · Taieb et al., 2017 · Open in CIViC

This clinical study was conducted with 30 patients with colorectal cancer harboring BRAF V600E (n = 29) or BRAF K601E (n=1) mutations, treated with a combination of cobimetinib and vemurafenib. Of the… (full text at CIViC)

PMID 36409971 · Klute et al., 2022 · Open in CIViC

A patient with colorectal cancer harboring a CAD-ALK fusion gene was treated with the ALK inhibitor entrectinib, resulting in durable objective tumor response. A CT scan four weeks after treatment ini… (full text at CIViC)

PMID 26633560 · Amatu et al., 2015 · Open in CIViC

A patient with right-sided, MSI-High and CCDC6-RET positive metastatic colorectal cancer showed complete response to the selective RET inhibitor RXDX-105. The patient remained progression-free after 1… (full text at CIViC)

PMID 29538669 · Pietrantonio et al., 2018 · Open in CIViC

In a clinical study including 105 patients with resectable colorectal carcinomas, a Kaplan-Meier analysis showed a significant association between CD44v5 high expression and worse free time of disease… (full text at CIViC)

PMID 15300427 · Vizoso et al., 2004 · Open in CIViC

112 patients with rectal cancer who received 5-FU based chemotherapy and surgery were retrospectively analyzed for expression of Ki67, TS, BAX, EpCAM, p53, p21, EGFR, CD44, CD133, CD166, HIF1α and ALD… (full text at CIViC)

PMID 24708484 · Sim et al., 2014 · Open in CIViC

Patients with stage II/III colorectal cancer were analyzed for expression of CDX2 (by microarray and IHC). In the discovery (466 patients) and validation sets (314 patients), 5-year DFS was lower amon… (full text at CIViC)

PMID 26789870 · Dalerba et al., 2016 · Open in CIViC

In patients with stage II colon cancer, positive CDX2 status was associated with longer overall survival.

PMID 26789877 · Boland et al., 2016 · Open in CIViC

In a clinical study including 164 patients, CEACAM1-L dominant expression is significantly associated with decreased OS by a multivariate analysis (p = 0.02).

PMID 21413011 · Ieda et al., 2011 · Open in CIViC

In a clinical study including 67 patients with liver metastases, enhanced CEACAM1-S expression in the state of CEACAM-L dominance at the primary tumor invasion front is significantly correlated with d… (full text at CIViC)

PMID 29180203 · Yamaguchi et al., 2017 · Open in CIViC

CIC knockout conferred resistance to trametinib in KRAS G13D (HCT116) and BRAF V600E (HT29) colon cancer cell lines.

PMID 28178529 · Wang et al., 2017 · Open in CIViC

CIC knockout conferred resistance to vemurafenib in BRAF V600E (HT29) colon cancer cells.

PMID 28178529 · Wang et al., 2017 · Open in CIViC

Frequency of point mutations in exon 3 β-catenin gene is low in our population. It would be interesting to increase the population size to test the clinically relevant influence in the prognosis found… (full text at CIViC)

PMID 25313745 · Rafael et al., 2014 · Open in CIViC

Expression of DCC was a strong positive predictive factor for survival in both stage II and stage III colorectal carcinomas. In patients with stage II disease whose tumors expressed DCC, the five-year… (full text at CIViC)

PMID 8929264 · Shibata et al., 1996 · Open in CIViC

In HCT-116, HT-29, and SW620 colorectal cancer cells, shRNA-mediated reduction of DHFR expression significantly increased sensitivity to fluorouracil, as measured by decreased IC50. DHFR and GGH knock… (full text at CIViC)

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

Nuclear expression of DICKKOPF-1 was identified in 15% of 699 patients with colorectal cancer and was associated with decreased progression-free survival (PFS) and overall survival (OS) after chemothe… (full text at CIViC)

PMID 25788273 · Aguilera et al., 2015 · Open in CIViC

shRNA-mediated depletion of DPYS expression significantly increased fluorouracil cytotoxicity in HCT-116, HT-29, and SW620 colorectal cancer cells, with approximately 3- to 7-fold decreases in IC50.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

shRNA-mediated DTYMK knockdown increased fluorouracil sensitivity, decreasing IC50 approximately threefold in HT-29 cells and fivefold in HCT-116 cells.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

Reduced DUT expression by shRNA increased fluorouracil sensitivity, producing approximately 13-fold and threefold reductions in IC50 in HCT-116 and SW620 cells, respectively.

PMID 21449674 · Muhale et al., 2011 · Open in CIViC

226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high E… (full text at CIViC)

PMID 23374602 · Pentheroudakis et al., 2013 · Open in CIViC

87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and … (full text at CIViC)

PMID 18794099 · Personeni et al., 2008 · Open in CIViC

In this meta-analysis (14 studies, 1021 patients), EGFR gene copy number (GCN) was predictive of improved progression free survival (PFS) and overall survival (OS) with cetuximab or panitumumab regard… (full text at CIViC)

PMID 24653627 · Shen et al., 2014 · Open in CIViC

Case report describing a 63-year-old patient with colorectal adenocarcinoma. He started treatment with XELOX and bevacizumab. After findings of disease progression, they changed to bevacizumab and FOL… (full text at CIViC)

PMID 32162810 · Li et al., 2020 · Open in CIViC

Case report describing a 63-year-old patient with colorectal adenocarcinoma with disease progression after treatment with XELOX-bevacizumab and bevacizumab-FOLFIRI. After the detection of EGFR aberrat… (full text at CIViC)

PMID 32162810 · Li et al., 2020 · Open in CIViC

Patients with refractory colorectal cancer expressing immunohistochemically detectable EGFR were randomly assigned to receive treatment with cetuximab (n=287) or receive supportive care alone (n=285).… (full text at CIViC)

PMID 18003960 · Jonker et al., 2007 · Open in CIViC

57 patients with chemorefractory colorectal cancer expressing EGFR (IHC staining) were treated with single-agent cetuximab in this phase 2 study. Five patients (9%; 95% CI, 3% to 19%) achieved a parti… (full text at CIViC)

PMID 14993230 · Saltz et al., 2004 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC

Next-generation sequencing data from cfDNA of 1,397 patients with colorectal cancer identified a novel cluster of extracellular domain (ECD) mutations in EGFR, mediating resistance by blocking binding… (full text at CIViC)

PMID 29196463 · Strickler et al., 2018 · Open in CIViC